Industries

Contract Research Organisations (CRO)

CROs live and die by writing throughput and audit posture. TraceDraft accelerates CSR, protocol, safety-narrative and medical-writing delivery with source-traceable AI; GxP Copilot keeps your validated clinical technology estate audit-ready.

Quick chat on WhatsAppHuman review at every gatePart 11 readyISO 9001 & 27001 certified

FDAEMAMHRAPMDACDSCOGAMP 5ICH Q921 CFR Part 11

In short

For a contract research organisation the binding constraint is usually throughput rather than compliance posture. Many studies run across many sponsors, each with their own templates and expectations, so pressure falls on clinical writing capacity and on demonstrating consistent oversight across sponsors — rather than on validating a few manufacturing systems deeply.

Roadblocks

Identify The Roadblocks Slowing Your Growth

These challenges compound: cycles slow, scaling gets harder, and inspection posture drifts.

01Writer capacity is the binding constraint

02Sponsor audits with tight timelines

03eTMF quality drift

04AI usage in regulated writing lacks assurance

Regulations

Regulations We Cover

Every CRO engagement is mapped to the regulations your inspectors will use.

Clinical
research

ICH E3 / E6 (R2/R3)
21 CFR Part 11
EU Annex 11 / Annex 22

Where validation sits

01Study start-upCTMSeTMFEssential documents filed on time
02Data captureEDCePROIRTAudit trails on trial data
03Samples and labsLIMSSample trackingChain of custody for every sample
04AnalysisStatistical computing environmentAnalyses that can be reproduced
05ReportingMedical writingDocument managementA CSR traceable to its source

Where validated systems sit across a typical CRO value chain, and what an inspector looks at in each stage. Typical systems shown; your estate will differ.

For CRO

Services & Products For Contract Research Organisations (CRO)

Services

Medical Writing
CSR Authoring
Protocol Writing
Safety Narratives
Clinical Operations

Products

Writer Capacity: The Binding Constraint in CRO Delivery

Clinical writing throughput is the single most reliable predictor of CRO delivery performance. Protocols, study reports, investigator brochures, and safety narratives all require qualified medical writers — and the supply of experienced GxP writers is structurally limited relative to global clinical trial volume. CROs that compete on timeline commitments without adequate writing capacity either miss milestones or deliver first drafts that require extensive sponsor revision, both of which damage sponsor relationships and constrain future awards.

TraceDraft addresses the throughput bottleneck directly. By automating the structural and reference-linkage components of clinical document generation — ingesting protocol, SAP, and TLG outputs to produce an ICH E3-structured CSR first draft with source traceability built in — TraceDraft removes the hours that experienced writers spend on mechanical structuring. The result is that your existing writing team delivers more documents in the same time, or that less-experienced writers produce first drafts that senior writers can efficiently review rather than reconstruct.

ICH E6(R3) and the Evolving GCP Audit Standard

ICH E6(R3) represents the most significant revision to GCP standards in two decades. Its core change is the explicit adoption of a risk-based, quality-by-design approach: sponsors and CROs are expected to identify the critical data and processes that matter most for subject safety and data integrity, and to focus monitoring and oversight proportionately. The traditional 100% SDV model is replaced by a risk-proportionate approach where the depth of verification is calibrated to the risk of error.

For CROs, ICH E6(R3) creates a new documentation obligation: the risk assessment that drives the monitoring strategy must be documented and defensible. Sponsor auditors will increasingly ask not just whether monitoring was performed, but whether the monitoring strategy was appropriate for the specific risks of the trial. GxP Copilot provides the audit trail for the risk-based monitoring decisions — linking the risk assessment to the monitoring plan, documenting the actual monitoring activities performed, and flagging deviations from the planned approach for documented review.

Have a document deadline coming?Talk to a CRO lead, or chat with us on WhatsApp.

eTMF Quality and Audit Posture

The electronic Trial Master File is the primary evidence base for GCP compliance in a clinical trial. Its quality — completeness, accuracy, contemporaneity, and accessibility — is assessed in both sponsor audits and regulatory inspections. eTMF quality drift is a persistent problem in long-duration trials: documents accumulate in the TMF without systematic review, filing is not contemporaneous, and the TMF completeness metric at any given moment may not reflect the actual document population that the trial has generated.

Cybroscape's clinical technology validation practice covers the major eTMF platforms — Veeva Vault TMF, Wingspan, and ISI eTMF — with validated deployments and ongoing TMF quality monitoring frameworks. GxP Copilot's document tracking capability provides real-time visibility into TMF completeness against the TMF Reference Model, with automated alerts for missing expected documents at defined trial milestones. This proactive approach catches eTMF gaps during the trial rather than at the end-of-trial inspection when remediation is expensive and high-risk.